L. Nathan Tumey
Associate Professor Binghampton University
L. Nathan Tumey joined Binghamton University in 2017, following 15 years of medicinal chemistry experience in the pharmaceutical and biotechnology industry. His research focuses on the design of ADCs for the treatment of cancer, autoimmune disorders and rare diseases. Specific research projects include immune-stimulating antibody conjugates, glucocorticoid-antibody conjugates, legumain-cleavable linkers and site-specific conjugation technology. Tumey is a leading expert in ADC technology, particularly as it applies to bioconjugation, linker design and immune-modulating payloads. He is a frequent consultant at various biotechnology and pharmaceutical companies and serves on the scientific advisory board of multiple ADC-related organizations.
Tumey received his doctorate in chemistry from Duke University in 2001, under the supervision of Michael Pirrung. During his years in the pharmaceutical industry, Tumey was a key leader in multiple drug-discovery programs, including the development of 5HT2c agonists for obesity, PKC-theta inhibitors for asthma, IRAK4 inhibitors for rheumatoid arthritis and ADCs for the treatment of cancer.
Seminars
Immune-modulating ADCs represent a class of non-cytotoxic payloads receiving increased attention as the field looks to diversify ADC mechanisms beyond classical Topo1 and MMAE therapies.
Attend this workshop to cover the history of immune-stimulating therapies and the progress being made to make effective ADC payloads, alongside the emerging development of immune-modulating ADCs expanding applications outside of oncology.
Workshop highlights include:
- Overviewing the ISAC field to contextualize clinical learnings and the opportunity of ISACs as an alternative, non-cytotoxic ADC mechanisms
- Delving into TLR7/8 and STING agonist development to understand which immune-stimulating molecules make effective ADC payloads
- Assessing the emergence of immunesuppressing ADCs leveraging glucocorticoid mechanisms for ISAC applications outside of oncology
